Share Price | Biohaven Ltd. Stock Analysis & Recommendation

Q: Is Biohaven Ltd. technically bullish or bearish?

As of 15 August 2025, the technical trend for Biohaven Ltd. has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD remains bearish. The Bollinger Bands show a bullish signal on the weekly timeframe but a mildly bearish signal on the monthly. Daily moving averages are mildly bearish, and the KST is bearish on the weekly. Dow Theory presents a mildly bearish outlook weekly and mildly bullish monthly. The On-Balance Volume is mildly bearish across both timeframes.In terms of performance, Biohaven has significantly underperformed the S&P 500, with a year-to-date return of -58.45% compared to the S&P's 12.22%, and a one-year return of -60.61% versus the S&P's 17.14%. Overall, the current technical stance is mildly bearish, driven by mixed signals across various indicators.

Q: What does Biohaven Ltd. do?

Overview: Biohaven Ltd. operates in the Pharmaceuticals & Biotechnology industry and is classified as a small-cap company.Financial Snapshot: Net Profit: -222 Million (Quarterly Results - Mar 2025) Market Cap: USD 1,486.76 Million (Small Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -1.23 Return on Equity: -342.43% Price to Book: 5.73Contact Details: Details: No Company Details Available Registrar Address: Not available.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

691.75 k

Shareholding (Jun 2026)

FII

12.08%

Held by 121 FIIs

DII

81.66%

Held by 47 DIIs

Promoter

6.25%

Is Biohaven Ltd. technically bullish or bearish?

20-Sep-2025

As of August 15, 2025, Biohaven Ltd. shows a mildly bearish technical trend with mixed signals across indicators, significantly underperforming the S&P 500 with year-to-date and one-year returns of -58.45% and -60.61%, respectively.

View full answer

How big is Biohaven Ltd.?

22-Jun-2025

As of Jun 18, Biohaven Ltd. has a market capitalization of 1,486.76 million, with net sales of 0.00 million and a net profit of -888.59 million over the last four quarters. Shareholder's funds are 423.44 million, and total assets amount to 615.11 million.

View full answer

What does Biohaven Ltd. do?

22-Jun-2025

Biohaven Ltd. is a small-cap pharmaceutical and biotechnology company with a market cap of approximately $1.49 billion. As of March 2025, it reported a net profit loss of $222 million and has no dividend yield.

View full answer

Compare Biohaven Ltd. with Similar Stocks

Neumora Therapeutics, Inc.Harmony Biosciences Holdings, Inc.Xenon Pharmaceuticals, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 1,259 Million (Small Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.45

Return on Equity

-1,427.70%

Price to Book

24.18

Revenue and Profits:

Net Sales:

(Quarterly Results - Jun 2026)

Net Profit:

-137 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

4.79%

6 Months

59.24%

1 Year

-0.7%

2 Years

-64.79%

3 Years

-17.28%

4 Years

0.0%

5 Years

0.0%

Biohaven Ltd. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-17.97%

EBIT to Interest (avg)

-732.47

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.23

Sales to Capital Employed (avg)

Tax Ratio

0.09%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

24.18

EV to EBIT

-1.59

EV to EBITDA

-1.60

EV to Capital Employed

-51.05

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-1427.70%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Bearish

RSI

No Signal

Bullish

Bollinger Bands

Mildly Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Bearish

Dow Theory

Mildly Bullish

No Trend

OBV

Mildly Bullish

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Jun 2026

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 68 Schemes (28.37%)

Foreign Institutions

Held by 121 Foreign Institutions (12.08%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'26 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2026 is 0.00% vs 0.00% in Jun 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2026 is 30.69% vs 38.06% in Jun 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'26",
        "Jun'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-124.30",
          "val2": "-210.60",
          "chgp": "40.98%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-14.60",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-137.30",
          "val2": "-198.10",
          "chgp": "30.69%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 12.71% vs -107.35% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-741.20",
          "val2": "-881.20",
          "chgp": "15.89%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.70",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-738.80",
          "val2": "-846.40",
          "chgp": "12.71%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'26 - YoY

Jun'26

Jun'25

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-124.30

-210.60

40.98%

Interest

0.00

Exceptional Items

-14.60

0.00

Consolidate Net Profit

-137.30

-198.10

30.69%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2026 is 0.00% vs 0.00% in Jun 2025

Consolidated Net Profit

YoY Growth in quarter ended Jun 2026 is 30.69% vs 38.06% in Jun 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-741.20

-881.20

15.89%

Interest

0.00

Exceptional Items

0.70

0.00

Consolidate Net Profit

-738.80

-846.40

12.71%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 12.71% vs -107.35% in Dec 2024

All Annual Results

Company CV

About Biohaven Ltd.

Biohaven Ltd.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available